Latest news with #Optibumin25
Yahoo
29-04-2025
- Business
- Yahoo
InVitria Launches Optibumin® 25, the First Recombinant 25% Human Serum Albumin for Closed-System Biomanufacturing
JUNCTION CITY, Kan., April 29, 2025--(BUSINESS WIRE)--InVitria, a leading developer of recombinant, chemically defined components for biomanufacturing, has announced the launch of Optibumin® 25, the first and only recombinant human serum albumin (rHSA) available as a 25% solution. Designed for closed-system workflows, Optibumin 25 is a high-purity alternative to plasma-derived albumin, enabling safer, more consistent manufacturing in cell and gene therapy applications. For decades, plasma-derived HSA has presented regulatory and supply chain challenges, including batch variability and pathogen risks. Optibumin 25 eliminates these issues by offering a chemically defined, animal-origin-free, GMP-compliant alternative. It supports regulatory compliance while improving scalability, sterility, and formulation performance. "Optibumin 25 directly replaces plasma-derived 25% HSA while enhancing process control and reducing regulatory risk," said Scott Deeter, CEO at InVitria. "It enables the kind of consistency required for clinical and commercial-scale production." Manufactured in an ISO 9001-certified, cGMP-compliant facility, Optibumin 25 is optimized for downstream processing, formulation, and cryopreservation workflows. The product is currently available in 100 mL single-use bags and is suitable for integration into viral vector manufacturing, stem cell preservation, vaccine formulation, and regenerative medicine. Key Benefits: First recombinant 25% HSA designed for closed systems Animal-origin-free and chemically defined GMP-ready and scalable to commercial volumes Stable, sterile, and contamination-resistant To learn more visit: About InVitria InVitria develops and manufactures high-performance, animal-origin-free supplements and excipients that support regulatory compliance and product consistency in biologics manufacturing. Its recombinant portfolio enables safer, scalable alternatives to blood-derived materials in cell and gene therapy, vaccine development, and regenerative medicine. InVitria products are manufactured in the United States in cGMP-compliant, ISO 9001-certified facilities. View source version on Contacts Alexia ArmstrongDirector of MarketingAarmstrong@ InVitria, Inc.2718 Industrial Drive, Junction City, KS 66441Phone: 401-636-1969 Sign in to access your portfolio
Business Wire
29-04-2025
- Business
- Business Wire
InVitria Launches Optibumin® 25, the First Recombinant 25% Human Serum Albumin for Closed-System Biomanufacturing
JUNCTION CITY, Kan.--(BUSINESS WIRE)--InVitria, a leading developer of recombinant, chemically defined components for biomanufacturing, has announced the launch of Optibumin® 25, the first and only recombinant human serum albumin (rHSA) available as a 25% solution. Designed for closed-system workflows, Optibumin 25 is a high-purity alternative to plasma-derived albumin, enabling safer, more consistent manufacturing in cell and gene therapy applications. Optibumin® 25 is the first recombinant 25% human serum albumin for closed-system biomanufacturing, offering consistency, sterility, and GMP compliance. Share For decades, plasma-derived HSA has presented regulatory and supply chain challenges, including batch variability and pathogen risks. Optibumin 25 eliminates these issues by offering a chemically defined, animal-origin-free, GMP-compliant alternative. It supports regulatory compliance while improving scalability, sterility, and formulation performance. 'Optibumin 25 directly replaces plasma-derived 25% HSA while enhancing process control and reducing regulatory risk,' said Scott Deeter, CEO at InVitria. 'It enables the kind of consistency required for clinical and commercial-scale production.' Manufactured in an ISO 9001-certified, cGMP-compliant facility, Optibumin 25 is optimized for downstream processing, formulation, and cryopreservation workflows. The product is currently available in 100 mL single-use bags and is suitable for integration into viral vector manufacturing, stem cell preservation, vaccine formulation, and regenerative medicine. Key Benefits: First recombinant 25% HSA designed for closed systems Animal-origin-free and chemically defined GMP-ready and scalable to commercial volumes Stable, sterile, and contamination-resistant To learn more visit: About InVitria InVitria develops and manufactures high-performance, animal-origin-free supplements and excipients that support regulatory compliance and product consistency in biologics manufacturing. Its recombinant portfolio enables safer, scalable alternatives to blood-derived materials in cell and gene therapy, vaccine development, and regenerative medicine. InVitria products are manufactured in the United States in cGMP-compliant, ISO 9001-certified facilities.
